Modality
Vaccine
MOA
IL-13i
Target
SMN2
Pathway
Wnt
RSV
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
~Oct 2018
→ ~Jan 2020
NDA/BLA
~Apr 2020
→ ~Jul 2021
Approved
Oct 2021
→ Jan 2030
ApprovedCurrent
NCT07920608
898 pts·RSV
2021-10→2030-01·Not yet recruiting
898 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-01-083.8y awayPh3 Readout· RSV
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
Approved
Not yet…
Catalysts
Ph3 Readout
2030-01-08 · 3.8y away
RSV
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07920608 | Approved | RSV | Not yet recr... | 898 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |